Portage Biotech Inc

Portage Biotech Inc. is a clinical-stage immuno-oncology company dedicated to developing innovative therapies for cancer treatment. Their focus is on advancing first-in-class treatments that target known checkpoint resistance pathways, aiming to improve long-term treatment response and quality of life for patients. Portage Biotech is developing novel agents that target immune checkpoints, which are proteins that regulate the immune system's response to cancer cells, to develop agents that augment the immune system's response to cancer cells. They are exploring the potential of combining their checkpoint inhibitors with other therapies, such as chemotherapy and targeted therapies, to enhance treatment effectiveness. Portage Biotech has a portfolio of six technology platforms, yielding 14 candidates targeting various cancer resistance pathways. Their platform includes small molecule adenosine inhibitors (PORT-6, PORT-7, and PORT-8), and invariant natural killer T cell engagers (PORT-2 and PORT-3) to activate the immune response in patients with PD-L1-negative tumors.

Jobs: